Literature DB >> 7050043

The mechanisms of cytotoxicity and chemosensitization by misonidazole and other nitroimidazoles.

J M Brown.   

Abstract

This paper attempts to review and interpret the various aspects of the interaction of the electron-affinic drug misonidazole (MISO) with cells in vitro and tumors in vivo. Specifically three topics are covered: (1) The preferential toxicity of MISO to hypoxic cells; (2) The sensitization of cells in vitro in chemotherapeutic agents by hypoxic pretreatment with MISO (the "preincubation effect"); (3) The chemosensitization of tumors in vivo by MISO. It is concluded that hypoxic cell cytotoxicity is not a result of the binding of nitroreduction products to the cellular target molecule (or molecules), but is a result of abstraction of H atoms by neutral radicals produced during nitroreduction. However, binding does occur, and this depletes intracellular glutathione which is capable both of inactivating these toxic radicals and repairing the target lesions. The preincubation effect--at least for bifunctional alkylating agents--is postulated to be a result of a combination of depletion of intracellular glutathione (which can "intercept" the alkylating agent), and increase in DNA interstrand cross-links. Finally, it is concluded that chemosensitization of tumors in vivo is a combination of the in vitro preincubation effect for the hypoxic cells, and an inhibition of repair of the chemotherapeutic agent damage to aerated, plateau-phase-like cells in the tumor. The former required nitroreduction, the latter does not.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7050043     DOI: 10.1016/0360-3016(82)90711-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  23 in total

1.  Misonidazole and CCNU chemotherapy for recurrent primary brain tumor.

Authors:  D S Fulton; R C Urtasun; S McKinnon; H Tanasichuk
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

2.  The effect of fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo.

Authors:  B A Teicher; T S Herman; S A Holden; K N Cathcart
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumour activity and acute toxicity of selected nitrogen mustards.

Authors:  F Y Lee; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine.

Authors:  D W Siemann
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

5.  In vitro potentiation of BCNU activity in rat brain tumour cells pretreated with misonidazole.

Authors:  D W Siemann; K Wolf; S Morrissey; K T Wheeler
Journal:  Br J Cancer       Date:  1984-06       Impact factor: 7.640

6.  Selective toxicity of nitracrine to hypoxic mammalian cells.

Authors:  W R Wilson; W A Denny; S J Twigden; B C Baguley; J C Probert
Journal:  Br J Cancer       Date:  1984-02       Impact factor: 7.640

7.  Preclinical pharmacokinetics of benznidazole.

Authors:  P Workman; R A White; M I Walton; L N Owen; P R Twentyman
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640

8.  Chemopotentiation in vivo: no loss of sensitization with fractionation.

Authors:  S A Hill; D W Siemann
Journal:  Br J Cancer       Date:  1984-10       Impact factor: 7.640

9.  Cytotoxic effect of misonidazole and cyclophosphamide on aerobic and hypoxic cells in a C3H mammary carcinoma in vivo.

Authors:  C Grau; S M Bentzen; J Overgaard
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

10.  Enhancement of nitrosourea cytotoxicity by misonidazole in vitro: correlation with carbamoylating potential.

Authors:  R T Mulcahy; N L Dembs; G A Ublacker
Journal:  Br J Cancer       Date:  1984-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.